BACKGROUND: Valvular heart disease is common and affects the mitral valve (MV) most frequently. Despite the prevalence of MV disease (MVD), the cellular and molecular pathways that initiate and perpetuate it are not well understood.
V alvular heart disease is common and affects ≈2.5% of all adults and ≈14% of adults >75 years of age in industrialized nations. 1 The mitral valve (MV) is most frequently diseased, followed by the aortic valve, whereas the right-sided valves (ie, tricuspid valve and pulmonic valve) are only rarely affected. 1 In the setting of systemic autoimmune and inflammatory diseases such as rheumatic fever and systemic lupus erythematosus, MV pathology is common. 2 The molecular and cellular pathways that connect systemic inflammation to valvular heart disease have not been delineated.
Animal models have been used to study the link between systemic inflammatory diseases and cardiovascular disease (CVD), but are largely focused on accelerated atherosclerosis. 3 Because of this, the majority of preclinical studies investigating cardiovascular inflammation use mouse models with genetic disruptions of lipid clearance. When fed a high-fat or Western diet, these mice reliably develop extreme and nonphysiological hypercholesterolemia, subsequently driving atherogenesis. 4 Although aortic valve lesions can arise in these mice, 5 MV disease (MVD) has historically been challenging to model experimentally.
Rheumatic heart disease (RHD) that follows inadequately treated group A streptococci infection in humans most commonly affects the MV. 6 During the progression of valvular RHD, mitral regurgitation progresses to mitral stenosis 6 because of the presence of longstanding fibrosis and MV remodeling induced by chronic inflammation. Immunization of rodents with cardiac myosin or group A streptococci peptides can induce the production of anticardiac autoantibodies that provoke cardiac valve inflammation. These models have provided information about the cellular and molecular drivers of valve inflammation in the setting of a systemic autoantibody-associated disease, 7, 8 and have also lent support to the molecular mimicry hypothesis. 9, 10 However, these studies, along with similar studies of valves from patients with rheumatic carditis, provide primarily descriptive insight. 6, 11, 12 Thus, the mechanisms by which rheumatic fever progresses to RHD remain undefined, and therapeutic intervention is largely limited to prophylactic antibiotics and, eventually, surgery. Although early recognition and treatment of group A streptococci infection has reduced the morbidity and mortality associated with RHD in developed countries, it remains a significant health challenge worldwide with an estimated mortality of >300 000 individuals annually. 12 Autoantibody formation occurs not only in rheumatic carditis, but also in many other forms of acquired CVD, arising both as a comorbidity of systemic autoimmunity (eg, Libman-Sacks endocarditis in systemic lupus erythematosus and the antiphospholipid antibody syndrome) and in the general population. 13, 14 The antigens targeted by CVD-associated autoantibodies are diverse and include cardiac-specific and ubiquitously expressed ones. 15, 16 Because of the well-studied connection between low-density lipoprotein and atherogenesis, the majority of animal studies have focused on autoantibodies with reactivity to apoliproteins, in particular, low-density lipoprotein and products of its metabolism (eg, oxidized low-density lipoprotein). These studies, however, provide conflicting information: both disease-ameliorating and disease-exacerbating roles for such autoantibodies have been reported 17, 18 ; whether these animal models correlate to human disease is also unclear. 19 We have described a mouse model of cardiac valve disease occurring in the context of chronic autoantibody-mediated arthritis. 20 T-cell receptor transgenic K/B.g7 arthritic mice develop fully penetrant, spontaneous-onset cardiac valve inflammation and fibrosis independently of disrupted lipid trafficking, dietary intervention, or experimentally induced hyperlipidemia. 21 As in humans, the left-sided valves are affected in K/B.g7 mice; MVD is 100% penetrant, whereas the aortic valve is affected less frequently. 20 Autoimmunity occurs spontaneously in K/B.g7 mice; no immunization is needed. Production of high-titer immunoglobulin G (IgG) autoantibodies reactive to a ubiquitously expressed antigen is critical to the systemic inflammatory process in this model. 22 Using constitutive knockout mice, we have previously shown that IgG-binding Fc receptors (FcγRs) are necessary for the MVD. 23 In related studies, we demonstrated that K/B.g7 MVD depends on mononuclear phagocytes (MNPs); systemic MNP depletion using clodronate liposomes confers protection from MV inflammation and fibrosis. 23 In the present study, we
Clinical Perspective
What Is New?
• We identify a critical population of CD301b/MGL2-expressing mononuclear phagocytes that orchestrates mitral valve inflammation and fibrosis in a mouse model. • We demonstrate that an analogous cell population is present in human inflammatory cardiac valve disease.
What Are the Clinical Implications?
• To our knowledge, these are the first studies to define the cellular and molecular mechanisms of cardiac valve inflammation and fibrosis occurring in the setting of systemic inflammatory disease, such as that seen in rheumatic heart disease.
• We identify multiple potential therapeutic targets that are required for mitral valve inflammation and fibrosis.
METHODS
The data, analytic methods, and study materials will be made available on request to other researchers for purposes of reproducing the results.
Animals
All animal experiments were conducted in accordance with /BoyJ (CD45.1-congenic C57BL/6). Standard housing in a specific pathogen-free facility was used in all studies.
Monoclonal Antibody Inhibition
All neutralizing monoclonal antibodies for in vivo use were purchased from BioXCell. Species-matched isotype control antibodies were purchased from Jackson ImmunoResearch. Antibody solutions were diluted with sterile 0.9% saline to a final concentration of 1 mg/mL. The dosing regimen consisted of twice-weekly intraperitoneal monoclonal antibody injections (200 μg monoclonal antibody in 200 μL 0.9% saline) for 4 weeks. The following clones were used: interleukin (IL)-6 (IL-6) (MP5-20F3), tumor necrosis factor (TNF) (MP6-XT22), TNF receptor (TNFR)-2 (TR75-54.7), very late antigen-4 (VLA-4) (PS/2), vascular cell adhesion molecule-1 (VCAM-1) (M/K-2.7), IL-18 (YIGIF74-1G7), granulocyte-macrophage colony-stimulating factor (MP1-22E9), chemokine (C-C motif) ligand 2 (2H5), and IL-1β (B122).
Tissue Isolation and Digestion
Following CO 2 euthanasia, mouse hearts were removed and placed in cold Roswell Park Memorial Institute medium with l-glutamine (Gibco) and 3% fetal bovine serum. MVs were then isolated with the aid of a dissection microscope. MVs were suspended in prewarmed Roswell Park Memorial Institute medium containing 3% fetal bovine serum, 10 mmol/L 2-[4-(2-hydroxyethyl)-piperazin-1-yl]-ethanesulfonic acid, 500 U/mL collagenase-2 (Worthington Biochemical, LS004174), and 20 U/mL DNase I (Worthington Biochemical, LS002006). Samples were incubated at 37°C using a water bath with periodic trituration for 1-hour total enzyme exposure. Enzyme activity was quenched using 10 mL cold Roswell Park Memorial Institute medium containing 3% fetal bovine serum, and the digested samples were centrifuged at 300g for 5 minutes at 4°C. Pellets were suspended in cold PBS containing 2% BSA (Roche) and passed through a 70-µm filter. To lyse erythrocytes, 0.100 mL ammonium-chloride-potassium lysis buffer was added to each valve sample, followed by incubation at room temperature for 3 minutes. The lysis was quenched by adding 1.5 mL of cold PBS containing 2% BSA. The remaining digested tissue samples were centrifuged at 300g for 5 minutes at 4°C, and the supernatants were discarded. The remaining pellets were suspended in PBS containing 2% BSA and used for flow cytometry analyses. For secondary lymphoid organs, the samples were macerated in ammonium-chloride-potassium buffer, passed through a 70-μm-cell strainer, incubated for 3 minutes to lyse erythrocytes, then centrifuged at 300g for 5 minutes at 4°C. The remaining pellets were suspended in 2% BSA in PBS and counted by using a hemocytometer. Axillary, brachial, cervical, inguinal, popliteal, para-aortic, and mesenteric lymph nodes, and spleen from each animal were pooled.
Intracellular Cytokine Staining
For analysis of TNF and IL-6 production in vivo, a bolus of 250 μg brefeldin A (eBioscience, 00-4506-51) in 200 μL saline was injected into the peritoneal cavity of each animal 3 hours before euthanasia. Lymphoid tissues and hearts were prepared as described above. For intracellular cytokine staining experiments, all sample buffers used before sample fixation contained 3 μg/mL brefeldin A. After staining surface antigens, samples were fixed and permeabilized as described above. Anti-TNF (clone MP6-XT22, BioLegend) and anti-IL-6 (clone MP5-20F3, BioLegend) antibodies were added at 1 μg/ mL for 30 minutes at room temperature, protected from light. Each sample was subsequently washed 3 times using PBS containing 2% BSA, filtered through a 70-µm-cell strainer, and used for flow cytometry analyses as described above.
Flow Cytometry
Antibodies with the following specificities were used (clones listed, purchased from BioLegend unless noted otherwise): CD3ε (145-2C11 and 17A2), CD4 (RM4-5 and GK1.5), B220 (RA3-6B2), Ly6G (1A8), CD11b (M1/70), F4/80 (BM8), CX3CR1 (SA011F11), Ly6C (AL-21, BD Biosciences), CD301b/macrophage galactose N-acetylgalactosamine-specific lectin 2 (MGL2) (URA-1), CD64 (X54-5/7.1), CD16.2 (9E9), CD49d (R1-2), Syk (5F5), CD49d (R1-2, eBioscience), and CD16/32 (2.4G2). Two to 5 million cells per lymphoid tissue sample were used in flow cytometry experiments. All cells liberated from collagenasedigested valve tissue were analyzed. Viability staining was conducted using Live/Dead Fixable Aqua (Thermo Fisher Scientific), Sytox Red (Thermo Fisher Scientific), and Ghost Violet-510 (Tonbo), according to each manufacturer's recommended protocol. FcγRs were blocked using anti-CD16/32 (α-FcγRII/III, Tonbo) at 5 μg/mL. Sample fixation and permeabilization were used for intracellular protein detection according to the manufacturer's protocol (Cytofix/Cytoperm, BD Biosciences). We used BD LSR Fortessa and BD LSR II cytometers equipped with FACSDiva software for data acquisition and FlowJo version 10 for data analyses. Quantification of fluorescence intensity was conducted by normalizing the geometric mean fluorescence intensities to their respective fluorescence-minus-one controls. 
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This ratio, averaged across experimental and biological replicates, is presented when indicated.
Mouse Tissue Histology
Hearts were excised and flash-frozen using Optimal Cutting Temperature medium over dry ice and isopentane slurry. Coronal sections were taken at 7-µm thickness with a cryostat (Leica CM3050 S) and stored at -80°C until used. Hematoxylin and eosin staining was conducted according to standard methods. Masson trichrome staining was conducted according to the manufacturer's recommendations (Abcam, ab150686). Cardiac valve thickness was measured as described previously 20, 23, 24 by using cellSens image acquisition software (Olympus). For immunofluorescence, sections were fixed in chilled acetone for 20 minutes. Nonspecific binding was blocked using PBS containing 5% normal donkey serum (Jackson ImmunoResearch), 0.1% Tween-20 (Sigma-Aldrich), 5 μg/mL anti-CD16/32 (2.4G2, Tonbo), and 5 μg/mL anti-CD64 (goat polyclonal, Santa Cruz Biotechnology). For indirect immunofluorescence, primary antibodies (anti-VCAM-1, 429-MVCAM.A, BioLegend; anti-TNFR1, rabbit polyclonal, Bioss; anti-TNFR2, TR75-42.4; anti-resistin-like molecule α/FIZZ-1, rabbit polyclonal, Peprotech; anti-arginase-1, rabbit polyclonal, Invitrogen) were used at a concentration of 5 μg/mL and incubated overnight in a humidified staining box at 4°C in PBS containing 5% normal donkey serum and 0.1% Tween-20. Secondary antibodies matched to the species of the blocking serum (or streptavidin-conjugated fluorochromes when detecting biotin-conjugated primary antibodies) were purchased from Jackson ImmunoResearch and used at a 1:800 dilution in PBS containing 2.5% normal donkey serum and 0.1% Tween-20. For direct immunofluorescence, all fluorochrome-conjugated antibodies (anti-CD301b/MGL2, URA-1; anti-CD64, X54-5/7.1; anti-CD45.1, A20; CD45.2, 104) were applied overnight at 4°C in a humidified staining box using a concentration of 5 μg/mL in PBS containing 5% normal donkey serum and 0.1% Tween-20, protected from light. Hoechst 33342 (Thermo Fisher Scientific) at 1 μg/mL in PBS was applied for 10 minutes to counterstain nuclei. Samples were mounted using antifade medium (Thermo Fisher Scientific) and imaged using an Olympus BX51 or a Leica DM6000B. For biotinylated antibodies, in addition to the blocking method described above, endogenous biotin blocking was performed according to the manufacturer's protocol (Abcam, ab3387). Exposures were matched to negative staining in isotype controls when appropriate. The FIJI distribution of ImageJ (National Institutes of Health) was used for image analysis.
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Ablation of Mgl2-Expressing Cells
Transgenic mice containing a diphtheria toxin receptor construct within the Mgl2 gene 26 were crossed to the K/B.g7 background. Beginning at 4 weeks of age, intraperitoneal injections of 1 μg diphtheria toxin (Sigma-Aldrich, D0564) in 100 μL PBS were given to each animal every other day and continued until 8 weeks of age. Histological assessment of MV inflammation and fibrosis was conducted as described above.
Statistics
Graphpad (Prism) was used for all statistical analyses. Twotailed Mann-Whitney, nonparametric tests were used for comparisons between 2 groups. For comparisons involving ≥3 groups, 1-way ANOVA with the post hoc Tukey test for multiple comparisons was used. Statistical significance was defined as P<0.05 and indicated as *P<0.05, **P<0.01, and ***P<0.005. Sample sizes are listed in the figures and figure legends.
Extended Methods
Additional experimental methods can be found in the onlineonly Data Supplement included with this article (human heart valve histology, tissue clearing and MV whole-mount imaging, image analysis, anti-glucose-6-phosphate isomerase [GPI] titers and arthritis scoring, and bone marrow chimeras).
RESULTS
Fully Penetrant, Fibroinflammatory Cardiac Valve Pathology in K/B.g7 Mice
The K/B.g7 mouse develops systemic inflammation resulting from expression of a transgenic T-cell receptor termed KRN that has specificity for a self-peptide derived from GPI. T-cell activation occurs when antigenpresenting cells expressing the I-A g7 major histocompatibility complex-II present endogenous GPI peptides to KRN-expressing T lymphocytes. These T cells then provide help to B lymphocytes, leading to their activation and, ultimately, production of high-titer anti-GPI autoantibodies, primarily IgG1 (summarized in Figure 1A ). [27] [28] [29] Although the inflammatory process in K/B.g7 mice occurs systemically, the primary disease manifestations are fully penetrant fibroinflammatory cardiac valve disease and erosive polyarthritis. 20, 23, 24, 30 MV inflammation begins at 3 weeks of age; by 8 weeks, accumulation of inflammatory cells and interstitial thickening is obvious ( Figure 1B ). Masson trichrome staining provides a qualitative demonstration of the fibrotic and inflammatory process present within the inflamed MVs of K/B.g7 mice ( Figure 1C ). Collagen deposition characteristically results from thickening of the lamina fibrosa, predominantly near the high-pressure left ventricle lumen (left side of both images in Figure 1C ). By 8 weeks, MVs of K/B.g7 mice are fibrotic and thickened ≈2.5-fold relative to noninflamed B.g7 controls (lacking the KRN transgene) and remain so chronically ( Figure 1D ). Valve hydroxyproline content, a measure of collagen deposition, is similarly elevated ( Figure 1E Figure 1F ), an observation consistent with our prior studies demonstrating that systemic depletion of phagocytes using clodronate liposomes prevents K/B.g7 MV inflammation and fibrosis. 
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To determine whether the MNPs arise from valveresident precursors or are recruited from the circulation, we generated bone marrow (BM) chimeric mice. BM cells from inflamed K/BxN mice (equivalent to K/B.g7) congenically expressing CD45.1 were transferred intravenously to sublethally irradiated CD45. A, K/B.g7 mice develop systemic inflammation and autoantibody production following activation of T lymphocytes bearing a transgenic T-cell receptor (TCR, termed KRN) that recognizes a peptide derived from glucose-6-phosphate-isomese (GPI) presented in the context of the I-Ag7 major histocompatibility complex-II expressed on professional antigen-presenting cells (APCs). B, K/B.g7 mice develop fully penetrant cardiac valve inflammation and fibrosis beginning at 3 weeks of age (evident histologically by the appearance of adherent inflammatory cells at the mitral valve (MV)-atrial interface, bottom left image, red arrowheads) and by 8 weeks of age, the MV becomes dramatically thickened and diffusely inflamed (bottom right image). C, Masson trichrome staining of coronal sections at 8 weeks of age shows that, in noninflamed B.g7 control mice that lack expression of the transgenic KRN TCR, the MVs are homogeneous, thin, collagen-rich, and sparsely cellular (top), whereas age-matched K/B.g7 MVs (bottom) demonstrate dramatic structural alterations resulting in interstitial collagen deposition and diffuse infiltration of mononuclear inflammatory cells. 
Cx3cr1-Expressing Mononuclear Phagocytes Are Required for K/B.g7 Cardiac Valve Inflammation and Fibrosis
Cx3cr1 encodes CX3CR1, the fractalkine (CX3CL1) receptor, and is expressed broadly within the MNP system. 31 We crossed Cx3cr1-gfp mice to the K/B.g7 background. These mice contain an enhanced green fluorescent protein reporter construct in the endogenous Cx3cr1 locus (Figure 2A Figure 2B, bottom) . These CX3CR1-expressing cells bear morphological resemblance to a population of aortic and cardiac valve dendritic cells described recently, and also to atrioventricular node macrophages that facilitate cardiac conduction.
32,33 K/B.g7 mice homozygous for the Cx3cr1-gfp reporter allele lack endogenous CX3CR1 expression and are protected from MVD ( Figure 2C ). Flow cytometry of inflamed K/B.g7 mitral valves from Cx3cr1 gfp/wt mice demonstrates that the CX3CR1-expressing cells are nearly uniform in their expression of CD64/FcγRI, the high-affinity IgG receptor commonly used to delineate a macrophage phenotype ( Figure 2D ). Taken together, these data demonstrate that CX3CR1-expressing MNPs are present in the inflamed MVs and are required for valve pathology.
CD301b/MGL2-Expressing MNPs Are Required for K/B.g7 MV Inflammation and Fibrosis and Have Correlates in Human Inflammatory MV Pathology
The cell surface receptor CD301b/MGL2 is classically associated with type 2 inflammatory responses that dominate the reparative phase of wound healing. 34 Immunofluorescent staining demonstrates that CD301b/
MGL2
+ cells are distributed diffusely in inflamed K/B.g7 MVs and frequently colocalize with molecules associated with tissue repair and fibrosis including arginase-1 and resistin-like molecule α/FIZZ-1 ( Figure 3A , Figure  II in the online-only Data Supplement). 26, 35, 36 To determine whether CD301b/MGL2-expressing MNPs are critical for MV inflammation, we generated Mgl2-DTR mice on the K/B.g7 background. These mice express the diphtheria toxin receptor under control of the Mgl2 promoter ( Figure 3B, top) ; administration of diphtheria toxin ablates CD301b/MGL2-expressing cells. We find that diphtheria toxin-mediated ablation of CD301b/ MGL2-expressing MNPs at the time of MVD onset (Figure 3B, right) significantly reduces MV fibroinflammatory thickening ( Figure 3C and 3D) .
We next asked whether we could detect analogous cells expressing CD301/CLEC10A (the human ortholog to mouse CD301b/MGL2) in inflamed human MVs. Valve tissue samples were taken from patients with rheumatic carditis undergoing MV repair or replacement. Masson trichrome staining demonstrates characteristic histopathology features of rheumatic fever and RHD including perivascular inflammation and formation of granulomas (ie, Aschoff bodies) ( Figure III in the online-only Data Supplement). These samples representing an early stage of RHD that presented clinically as mitral regurgitation display a disorganized and disrupted collagen fiber network with poorly staining regions of high proteoglycan and glycosaminoglycan ( Figure 3D, top) . Immunostaining for human CD163 (pan-macrophage) and human CD301/CLEC10A demonstrates frequent colocalization of the markers ( Figure 3D, bottom) . Thus, like K/B.g7 MVD, human inflammatory MV pathology demonstrates accumulation of CD301-expressing macrophages. 
TNF-and IL-6-Producing
g7 Cardiac Valves and Promote Valve Inflammation and Fibrosis
We next sought to define the functional role for MNPs in K/B.g7 MV inflammation and fibrosis and hypothesized that they produce cytokines that drive MV inflammation. We tested this using intracellular cytokine staining and flow cytometry of inflammatory cells isolated from K/B.g7 MVs. The CX3CR1-expressing MNPs can be subdivided based on Ly6C expression, with Ly6C-low and Ly6C-high cells thought to represent early-and late-stage recruited cells, respectively. 35, 37, 38 Both of these fractions contain pathogenic CD301b/ MGL2 + cells, and TNF and IL-6 production is readily detected in them (the gating strategy used in identification of cytokine-producing cells is shown in Figure 4A ). Relative to pooled secondary lymphoid organs (axillary, 
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brachial, cervical, inguinal, popliteal, para-aortic and mesenteric lymph nodes, and spleen) of the same mice, the frequency of TNF-and IL-6-producing phagocytes isolated from inflamed MV tissue is significantly elevated, demonstrating enrichment of cytokine-producing phagocytes within the inflamed MVs ( Figure 4B ). To determine the functional role for either cytokine in K/B.g7 MVD, we used monoclonal antibody blockade of either TNF or IL-6 beginning at the onset of MV inflammation ( Figure 4C ). TNF or IL-6 neutralization resulted in qualitative and quantitative reductions in VCAM-1 intensity ( Figure 4D and 4E). In comparison with isotype control antibody-treated animals, blockade of either TNF or IL-6 significantly reduced MV fibrosis and thickening ( Figure 4F ). In addition, no effect on MV thickening was observed by using monoclonal antibody blockade of 
Syk Signaling in CX3CR1 + CD310b/ MGL2 + Phagocytes Drives TNF and IL-6 Production
We have previously demonstrated, using whole animal gene knockouts, that activation of IgG receptors (FcγRs, specifically FcγRIII/CD32 and FcγRIV/CD16.2) promotes MVD in K/B.g7 mice. 23 To determine if signaling downstream of activating FcγRs specifically in MNPs is necessary for K/B.g7 MVD, we used a conditional gene deletion approach using Cx3cr1-Cre. Signal transduction downstream of activating FcγRs is mediated by an immunoreceptor tyrosine-based activation motif-bearing signaling chain that recruits spleen tyrosine kinase (Syk) (Figure 5A, left) . To test whether this signaling pathway in MNPs is critical for MVD, we generated Figure 5C ). Similarly, the number of CD301b/MGL2-expressing MV cells is significantly reduced in mice lacking expression of MNP-Syk relative to Cre-negative littermates ( Figure 5D ). Intracellular cytokine staining and flow cytometry on MV inflammatory cells demonstrate that conditional MNP-Syk deletion leads to a qualitative ( Figure 5E ) and quantitative ( Figure 5F ) reduction in TNF and IL-6 expression from valve-infiltrating CD301b/ MGL2 + MNPs. Thus, MNP-Syk is required for the initiation and progression of MV inflammation and acts to promote TNF and IL-6 production from CD301b/MGL2 + MNPs in situ.
TNFR1 Promotes MVD Whereas TNFR2 Restrains It
TNFR1 and TNFR2 have different cellular expression patterns and induce context-dependent effects. 39, 40 To clarify the mechanism of TNF-dependent MVD, we first evaluated expression of TNFR1 and TNFR2 in inflamed MVs. Both receptors are readily detected in noninflamed control (B.g7) and inflamed (K/B.g7) MVs ( Figure 6A ). We therefore interrogated the contribution of each of these receptors to the development and progression of MVD.
We hypothesized that valve-resistant cell types (eg, endothelial cells and valvular interstitial cells) expressing TNFR1 are the main responders to TNF. To test this, we generated BM chimeras with sublethally irradiated Tnfr1 -/-:Rag1 -/-mice reconstituted with Tnfr1 +/+ K/B.g7 BM. Tnfr1
-/-age-matched mice were used as control recipients ( Figure 6B ). MV fibrosis and thickening developed normally in the control animals, whereas recipient mice lacking Tnfr1 expression on valve-resident cells failed to develop MVD ( Figure 6C) .
To assess the possible role of TNFR2, we used monoclonal antibody blockade according to timeline in Figure 6D . It is interesting to note that TNFR2 neutralization significantly exacerbated MV fibrosis and thickening in comparison with isotype control antibody-treated animals ( Figure 6E ), suggesting that TNFR2 normally inhibits MVD. Collectively, these studies demonstrate opposing roles for TNFR1 and TNFR2: TNFR1 promotes MVD in K/B.g7 mice whereas TNFR2 restrains it.
Accumulation of Valve-Infiltrating CX3CR1 + MNPs Depends on VCAM-1:VLA-4
Based on our studies demonstrating that K/B.g7 MVD requires expression of TNF or IL-6, and that these cytokines promote VCAM-1 expression in inflamed MVs (Figure 4) , we postulated that activation of the valve , and anti-TNF respectively; *P<0.05, **P<0.01). Scale bar in D equals 50 µm and applies to all images. Statistical differences in E and F were assigned using 1-way ANOVA with a post hoc Tukey test for multiple comparisons. FSC-H indicates forward scatter, height; IgG, immunoglobulin G; IL-6, interleukin-6; MGL2, macrophage galactose N-acetylgalactosamine-specific lectin 2; MNP, mononuclear phagocyte; MV, mitral valve; and TNF, tumor necrosis factor.
ORIGINAL RESEARCH ARTICLE
macrophage surface phenotype), relative to littermates lacking Cre expression. Thus, CX3CR1 + MNPs accumulate in K/B.g7 MVs mice via expression of VLA-4 and through interactions with VCAM-1 expressed on the cytokine-activated valve stroma.
Arthritis Progression and Autoantibody Titers: MV-Specific Pathogenesis
The progression of arthritis and anti-GPI IgG titers were assessed in all the experiments presented above (Meth- ORIGINAL RESEARCH ARTICLE ods in the online-only Data Supplement). In each setting, the interventions (eg, monoclonal antibody blockade, conditional gene deletions, BM chimeras) had no effect on the progression of arthritis or anti-GPI IgG production (Figures VI through IX in the online-only Data Supplement). Thus, K/B.g7 MVD progresses by distinct mechanisms from those contributing to joint pathology in the same animals. In addition, the reductions in valve inflammation and fibrosis highlighted herein are not the result of global suppression of inflammation, as demonstrated by unimpeded development of arthritis and autoantibody production.
DISCUSSION
Using complementary in vivo approaches including blocking antibodies, constitutive and conditional gene deletion, and targeted cell depletion, we define a critical inflammatory population of CD301b/MGL2-expressing MNPs that is required for MV pathology and demonstrate that similar cells are present in MV specimens from human patients with rheumatic carditis. Our findings are consistent with the working model shown in Figure 8 . Initial production of anti-GPI autoantibodies results from the interaction of selfreactive T and B cells (①). Binding of circulating IgG autoantibodies to activating IgG receptors (FcγRs) on valve-resident cardiac phagocytes (②) activates a Sykdependent signaling cascade, resulting in TNF and IL-6 production (③). MNP-derived TNF acts through TNFR1 on the radio-resistant cell populations in the valve stroma and interstitium (④), upregulating VCAM-1. Circulating VLA-4 + MNPs interact with VCAM-1 (⑤) and are recruited to the valve interstitium, where they assume a tissue-reparative phenotype characterized by expression of CD301b/MGL2 + (⑥).
26,34 
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To our knowledge, this is the first study to define the in vivo cellular and molecular mechanisms that mediate chronic autoimmune MV inflammation and fibrosis. More broadly, our findings advance the understanding of how circulating autoantibodies provoke cardiac pathology. 
The immune system's contribution to CVD has been studied extensively. 41 It is well known that patients with systemic inflammatory disorders (eg, rheumatoid arthritis, systemic lupus erythematosus) develop more accelerated and aggressive forms of CVD compared to the general population. 42 Independently of blood lipids, increased inflammatory biomarkers (eg, C-reactive protein, IL-6) positively correlate with the risk of adverse cardiovascular events. 43 Despite these observations, no currently Food and Drug Administration-approved therapies directly target elements of adverse cardiovascular inflammation. In recent years, much emphasis has been placed on understanding the mechanisms underlying immune-mediated cardiovascular remodeling. Medical management of CVD, however, has historically centered around blood lipids and, in particular, lowdensity lipoprotein reduction; a few large-scale clinical trials have directly evaluated the role of inflammation during the natural history of CVD.
The landmark CANTOS study (Canakinumab Antiinflammatory Thrombosis Outcome Study) provides direct confirmation for the role of inflammation in cardiovascular pathology. In this study, administration of an IL-1β-neutralizing antibody (canakinumab) to patients with a prior history of myocardial infarction and evidence of elevated systemic inflammation (as indicated by elevated serum C-reactive protein) significantly reduced adverse cardiovascular events. 45 IL-1β was chosen as a therapeutic target in view of its role in driving IL-6 production; serum levels of IL-6 demonstrate a strong, lipid-independent correlation with the risk of adverse cardiovascular outcomes. [43] [44] [45] Herein, we demonstrate a critical role for both IL-6 and TNF as drivers of chronic cardiac valve inflammation in K/B.g7 mice, whereas IL-1β blockade had no effect. Thus, the pathways by which cardiac inflammation arises are diverse. The results of CANTOS confirm the role for inflammation in CVD and underscore the importance of continued exploration of additional pathways by which immune dysregulation may contribute to its development. Although CANTOS provides much-needed confirmation of the inflammation hypothesis in atherosclerotic CVD, additional immune mechanisms undoubtedly also contribute to cardiovascular pathology.
We have defined a critical role for CD301b/MGL2-expressing MNPs in a mouse model of systemic autoimmunity-associated MVD. Beyond its association with MNP (eg, macrophage, dendritic cells) polarization during type 2 inflammatory responses in multiple disease models, 26, 34, 46 relatively little is known about the specific function(s) of CD301b/MGL2 and its human ortholog, CD301/CLEC10. Consistent with this, no 
prior studies have demonstrated that CD301b/MGL2 expression delineates a critical pathogenic MNP subset that is required for cardiovascular pathology. Most commonly, CD301b/MGL2 is used in a descriptive manner to designate an alternatively activated phenotype because of its association with canonical M2 macrophage polarization. Studies have shown that white adipose provides a niche for CD301b/MGL2 + MNPs. Therein, their functional roles are diverse and include regulation of whole-organism metabolic homeostasis through endocrine secretion of resistin-like molecule α/FIZZ-1.
34
The well-defined connection between derangements of metabolism (eg, diabetes mellitus, obesity) and cardiovascular risk tempts speculation about potential direct and indirect roles for adipose-residing CD301b/ MGL2-expressing MNPs during CVD progression. Further study of the biology of CD301b/MGL2-expressing cells will be needed to clarify our experimental observations. In particular, determination of the specific anatomic compartments from which pathogenic CD301b/ MGL2-expressing MNPs arise in K/B.g7 MVD, and their temporal dynamics during MVD progression, as well, will be greatly informative.
The most commonly used mouse models used to study lipid-mediated vascular remodeling and CVD are based on genetic disruption of lipid trafficking (ie, Apoe -/-and Ldlr -/-mice on a high-fat diet). These models are characterized by extreme, nonphysiological hyperlipidemia; how well they model human CVD is unclear, and the potential therapies that have emerged from these animal models failed to demonstrate efficacy in human clinical trials. Models that provide insight into other mechanisms underlying CVD pathology are therefore needed. Although K/B.g7 mice do develop mild spontaneous dyslipidemia on a normal chow diet, 21 they do not develop extreme hyperlipidemia. This model thus serves as a powerful tool to focus on the immune drivers of cardiovascular inflammation. Food and Drug Administration-approved therapies exist or are in development to target the proinflammatory mediators of CVD we have defined here, including TNF, IL-6, VLA-4, VCAM-1, and Syk. 47, 48 Thus, our study provides the basis for the rational design of clinical trials of agents such as these for patients with chronic inflammatory CVD. 
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